Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan van Meerbeeck

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
International Journal of Radiation Oncology, Biology, Physics|December 20, 2008
Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapyCary Dehing-Oberije, Shipeng Yu, Dirk De Ruysscher, et al.
Molecular Diagnosis & Therapy|December 16, 2019
Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical ConditionsLaure Sorber, Karen Zwaenepoel, Julie Jacobs, et al.
Oncotarget|July 1, 2015
The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancerChristophe Deben, An Wouters, Ken Op de Beeck, et al.
Clinical Lung Cancer|July 11, 2017
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural MesotheliomaGiorgio V Scagliotti, Rabab Gaafar, Anna K Nowak, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 19, 2010
Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patientsCary Dehing-Oberije, Dirk De Ruysscher, Steven Petit, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 8, 2005
(188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation studyBieke Lambert, Klaus Bacher, Luc Defreyne, et al.
Cancers|April 3, 2019
Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation ProtocolLaure Sorber, Karen Zwaenepoel, Julie Jacobs, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2011
Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062Mary E R O'Brien, Krzystof Konopa, Paul Lorigan, et al.
JTO Clinical and Research Reports|May 23, 2022
Implementing Lung Cancer Screening in Europe: Taking a Systems ApproachSuzanne Wait, Arturo Alvarez-Rosete, Tasnime Osama, et al.
Lancet (London, England)|June 5, 2007
Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic reviewDavid Gilligan, Marianne Nicolson, Ian Smith, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
International Journal of Radiation Oncology, Biology, Physics|December 20, 2008
Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapyCary Dehing-Oberije, Shipeng Yu, Dirk De Ruysscher, et al.
Molecular Diagnosis & Therapy|December 16, 2019
Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical ConditionsLaure Sorber, Karen Zwaenepoel, Julie Jacobs, et al.
Oncotarget|July 1, 2015
The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancerChristophe Deben, An Wouters, Ken Op de Beeck, et al.
Clinical Lung Cancer|July 11, 2017
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural MesotheliomaGiorgio V Scagliotti, Rabab Gaafar, Anna K Nowak, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 19, 2010
Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patientsCary Dehing-Oberije, Dirk De Ruysscher, Steven Petit, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 8, 2005
(188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation studyBieke Lambert, Klaus Bacher, Luc Defreyne, et al.
Cancers|April 3, 2019
Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation ProtocolLaure Sorber, Karen Zwaenepoel, Julie Jacobs, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2011
Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062Mary E R O'Brien, Krzystof Konopa, Paul Lorigan, et al.
JTO Clinical and Research Reports|May 23, 2022
Implementing Lung Cancer Screening in Europe: Taking a Systems ApproachSuzanne Wait, Arturo Alvarez-Rosete, Tasnime Osama, et al.
Lancet (London, England)|June 5, 2007
Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic reviewDavid Gilligan, Marianne Nicolson, Ian Smith, et al.
Pageof 6